Teva Pharm to launch Humira biosimilar as Q1 profit misses estimates

Teva Pharmaceutical Industries (TEVA.TA) said it was set to launch its long awaited biosimilar of AbbVie's (ABBV.N), opens new tab blockbuster arthritis drug Humira in the coming weeks after it posted mixed results in the first three months of 2024.